Alcon Reports Q3 2026 Financial Results and Narrows Full-Year Guidance

Alcon announced its third-quarter 2026 financial results, reporting net sales of $2.72 billion, which fell short of the $2.73 billion expected by analysts. The company experienced competitive pressure in its implantables segment, though this was partially offset by growth in consumables, equipment, and vision care. Consequently, Alcon narrowed its full-year 2026 guidance, now expecting constant-currency sales growth of 6% and core earnings per share growth of 12% to 14%. Management attributed the performance to ongoing competitive dynamics in specific markets. Following the announcement, the company's shares experienced a notable decline in trading.